Egetis Therapeutics AB (publ)

BST:P0F Stock Report

Market Cap: €131.4m

Egetis Therapeutics Valuation

Is P0F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of P0F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate P0F's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate P0F's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for P0F?

Key metric: As P0F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for P0F. This is calculated by dividing P0F's market cap by their current revenue.
What is P0F's PS Ratio?
PS Ratio31.4x
SalesSEK 46.10m
Market CapSEK 1.45b

Price to Sales Ratio vs Peers

How does P0F's PS Ratio compare to its peers?

The above table shows the PS ratio for P0F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average8x
HPHA Heidelberg Pharma
21.4x39.66%€146.3m
FYB Formycon
6.2x18.37%€429.9m
2INV 2invest
2.7xn/a€69.5m
BIO3 Biotest
1.6xn/a€1.4b
P0F Egetis Therapeutics
31.4x55.03%€1.4b

Price-To-Sales vs Peers: P0F is expensive based on its Price-To-Sales Ratio (31.4x) compared to the peer average (8.9x).

Price to Sales Ratio vs Industry

How does P0F's PS Ratio compare vs other companies in the DE Biotechs Industry?

10 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIO3 Biotest
1.6xn/aUS$1.62b
2INV 2invest
2.7xn/aUS$78.19m
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
P0F 31.4xIndustry Avg. 7.4xNo. of Companies10PS01632486480+
10 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: P0F is expensive based on its Price-To-Sales Ratio (31.4x) compared to the European Biotechs industry average (7.2x).

Price to Sales Ratio vs Fair Ratio

What is P0F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

P0F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio31.4x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate P0F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

AnalystConsensusTarget
Consensus Narrative from 5 Analysts
€1.76
Fair Value
64.7% undervalued intrinsic discount
5
Number of Analysts

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/05 08:49
End of Day Share Price 2025/01/06 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Egetis Therapeutics AB (publ) is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Patrick LangstromABG Sundal Collier Sponsored
Oscar Haffen LammBryan Garnier & Co